Recode Therapeutics Inc.

2 trials 1 recruiting Commercial sponsor

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

1 Recruiting

1 Completed trials

4 Countries active

2 Unique IMPs

100% Results reported

Phase I (Other)

Phase I (FiH)

Phase I (Other): 1 Phase I (FiH): 1

Oversight events:

1 corrective measure across 1 trial

View oversight register →

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Primary ciliary dyskinesia 1

Top IMPs

IVACAFTOR 1 RCT2100 1

All trials

2 total

A Phase 1/2, Multicenter Study Evaluating the Safety, Tolerability, and Biodistribution of RCT2100 with Single-Ascending Doses in Healthy Pa… Recruiting

2024-512169-15-00 Phase I (FiH) 2 countries IVACAFTOR; RCT2100
A Phase 1b study of inhaled RCT1100 in Adults with Primary Ciliary Dyskinesia Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mu… Ended

2023-510521-14-00 Phase I (Other) 2 countries

Showing 1–2 of 2 trials

← All sponsors A–Z